



ASX Release

31 October 2018

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 26
140 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
W: www.zeldatherapeutics.com

Contacts

Dr Richard Hopkins
Managing Director
+61 405 656 868
rhopkins@zeldatherapeutics.com

Monsoon Communications
Rudi Michelson
+61 3 9620 3333
rudym@monsoon.com

Directors

Dr Richard Hopkins
Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

Tickers:

Australia (ASX): ZLD
USA (OTCQB): ZLDAF

Ordinary Shares:

755,341,934

Options:

49,000,000

1,500,000 (\$0.04 – 6/2/2020)

*4,500,000 (\$0.04 – 6/2/2020)

1,000,000 (\$0.125 – 22/8/2021)

*2,000,000 (\$0.125 – 22/8/2021)

*40,000,000 (\$0.03125 – 17/11/2021)

* subject to vesting conditions

SEPTEMBER 2018 QUARTERLY REPORT

- Solid progress on all fronts
- New Managing Director commenced with Zelda
- Commenced Australian insomnia trial
- Observational autism trial in the USA underway
- Entered into strategic manufacturing and distribution agreement with European group HAPA Medical
- Medical advisory board expanded

The Board of **Zelda Therapeutics Ltd (ASX: ZLD, Zelda or the Company)** is pleased to provide an operational update to accompany its Appendix 4C for the three-month period to 30 September 2018.

OPERATIONAL PROGRESS

New Managing Director Commenced with Zelda

Zelda was delighted to welcome Dr Richard Hopkins as Managing Director after he formally commenced with the Company on 16 July.

Insomnia Trial

Zelda was pleased to announce the first patient received medication in its pioneering insomnia trial.

The clinical trial is being undertaken by the prestigious University of Western Australia (UWA) Centre for Sleep Science (CSS), which has state-of-the-art research facilities and is directed by Professor Peter Eastwood, National Health and Medical Research Council Senior Research Fellow.

It is anticipated that preliminary results from this clinical trial will be available in the first half of 2019. Should the trial be successful, it is the intention to rapidly commercialise this formulation as a clinically validated cannabis medication for treatment of insomnia. Commercialisation partners have been identified for key territories and active engagement is underway.

Autism Observational Trial

Subsequent to the end of the quarter, recruitment commenced for Zelda's autism observational trial, which is being conducted at a leading hospital in the USA. This trial is seeking to better understand the efficacy of medicinal cannabis treatment in existing patients and will work closely with patient advocacy groups.

This study is aiming to recruit up to 200 patients and will combine a number of key efficacy and safety measures, including clinical pharmacological data making it the first significant study of its kind.

Preliminary results are expected in the first half of 2019.

Partnership with HAPA Medical BV to manufacture and distribute Zelda products in Germany and Europe

Zelda was pleased to announce it had entered a strategic partnership with HAPA Medical BV, a European medicinal cannabis company focused initially on the important German market. The strategic partnership provides HAPA with first rights to distribute and/or manufacture Zelda's clinically validated formulations into the rapidly growing German market. With a population of 83 million people, Germany is forecast to become one of the world's largest single markets for medicinal cannabis. HAPA's in-house ability to manufacture specialised pharmaceuticals to stringent EU-GMP standards combined with its distribution network provides an attractive market entry pathway for Zelda.

New Appointments to Medical Advisory Board

Zelda appointed two leading medicinal cannabis experts to its Scientific and Medical Advisory Board. Professor David Casarett and Dr Dustin Sulak are internationally recognised as key opinion leaders in the clinical use of medicinal cannabis and are both based in the United States. These appointments further strengthen Zelda's world-class Scientific and Medical Advisory Board.

Corporate

The Company has continued to progress its core clinical and pre-clinical activities and has also established the foundations to rapidly commercialise its clinically validated formulations.

As Zelda continues to grow and expand its activities, it remains focused on generating shareholder value through identifying and securing new intellectual property and pursuing rapid a commercialisation strategy for its medicinal cannabis products.

The Company closed the quarter with a cash position of \$5.06 million.

Dr Richard Hopkins, Managing Director stated: *"We are delighted to have commenced the insomnia and autism trials, which represents a significant landmark for the Company. This was complemented by the strategic partnership with HAPA, which provides Zelda with access to one of the world's most significant markets for medicinal cannabis. The fact that HAPA are one of the few suppliers in the world who can manufacture to EU-GMP standards provides Zelda with a huge competitive advantage. With the results of the clinical trials expected during the first half of 2019, we are now well positioned to continue leveraging our strong strategic position into global markets."*

Tim Slate

Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics Ltd ("Zelda") is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A **human clinical trial programme** focused on insomnia and autism with activities in Australia and the USA.
- A **pre-clinical research programme** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer and cognitive decline.